Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,321 papers from all fields of science
Search
Sign In
Create Free Account
insulin aspart, insulin aspart protamine drug combination 30:70
Known as:
BIAsp 30
, biphasic insulin aspart 30:70
, biphasic insulin aspart 30
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
Broader (4)
Biphasic Insulins
Hypoglycemic Agents
Insulin Aspart
insulin, isophane
Narrower (1)
NovoLog Mix 70/30
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Biphasic insulin aspart 30: Better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes
M. Velojić-Golubović
,
D. Mikić
,
M. Pešić
,
D. Dimić
,
S. Radenković
,
S. Antić
Journal of Endocrinological Investigation
2009
Corpus ID: 27323166
Aim: This 3-month study compared the effect on overall glycemic control of adding biphasic insulin aspart 30 (BIAsp30) and…
Expand
2009
2009
A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study.
R. Thorisdottir
,
T. Parkner
,
Jian-wen Chen
,
N. Ejskjaer
,
J. Christiansen
Basic & Clinical Pharmacology & Toxicology
2009
Corpus ID: 11606315
The purpose of this study was to evaluate pharmacokinetic and pharmacodynamic profiles of pure insulin aspart and three different…
Expand
2007
2007
Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes
W. M. Bebakar
,
C. Chow
,
K. A. Kadir
,
S. Suwanwalaikorn
,
J. Vaz
,
O. Bech
Diabetes, obesity and metabolism
2007
Corpus ID: 11625074
Aim: To evaluate the efficacy and safety of adding biphasic insulin aspart 30 (BIAsp30; NovoMix® 30) to existing oral…
Expand
2005
2005
Improvement of glucose tolerance in type 2 diabetic patients: traditional vs. modern insulin regimens (results from the Austrian Biaspart Study).
Heidemarie Abrahamian
,
B. Ludvik
,
+4 authors
T. C. Wascher
Hormone and metabolic research = Hormon- und…
2005
Corpus ID: 41431036
OBJECTIVE Major advantages of modern insulin regimens containing premixed insulin analogues in comparison to traditional insulin…
Expand
2005
2005
Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week…
I. Raz
,
Stephen N. Stranks
,
+5 authors
J. Shaban
Clinical Therapeutics
2005
Corpus ID: 24853250
2005
2005
Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes.
I. Schmoelzer
,
A. de Campo
,
+4 authors
T. Wascher
Experimental and clinical endocrinology…
2005
Corpus ID: 9334426
BACKGROUND Premixed insulin analogues reduce postprandial hyperglycemia in patients with Type 2 diabetes in comparison to…
Expand
2005
2005
The pharmacokinetic and pharmacodynamic properties of biphasic insulin Aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin Aspart 30 (BIAsp 30).
Susanne Bott
,
C. Tusek
,
Lutz Heinemann
,
H. H. Friberg
,
Tim J. S. Heise
Experimental and clinical endocrinology…
2005
Corpus ID: 33425220
AIMS To evaluate the pharmacokinetic and pharmacodynamic properties of two different formulations of premixed analogue (mixed…
Expand
2005
2005
Pharmacokinetic profiles of biphasic insulin aspart 30/70 and 70/30 in patients with Type 1 diabetes: a randomized double‐blinded crossover study
J-W. Chen
,
T. Lauritzen
,
J. Christiansen
,
L. Jensen
,
W. Clausen
,
J. Christiansen
Diabetic Medicine
2005
Corpus ID: 9074435
Aims To compare pharmacokinetic characteristics of two biphasic insulin aspart (BIAsp) formulations: BIAsp30 and BIAsp70 (30…
Expand
Highly Cited
2003
Highly Cited
2003
Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes
J. Christiansen
,
J. Vaz
,
Ž. Metelko
,
M. Bogoev
,
I. Dedov
Diabetes, obesity and metabolism
2003
Corpus ID: 20066540
Objective: Biphasic insulin aspart 30 (BIAsp30) is a dual release formulation, containing 30% soluble and 70% protamine…
Expand
2003
2003
Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy.
I. Raz
,
U. Mouritzen
,
J. Vaz
,
Tommy Hershkovitz
,
J. Wainstein
,
I. Harman-boehm
Clinical Therapeutics
2003
Corpus ID: 26720409
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE